Konety BR, Dhawan V, Allareddy V, O'Donnell MA: Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer: is more cheaper? J Urol 2004;172:1056-61.

O'Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/Interferon Phase 2 Investigator Group: Interim results from a national multicenter phase ii trial of combination bacillus calmette-guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-93.

Joudi FN, O'Donnell MA: Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 2004;14:271-5.

Luo Y, Yamada H, Chen X, Ryan AA, Evanoff DP, Triccas JA, O'Donnell MA: Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 2004;137:24-34.

Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, Griffith TS: Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004;64:3386-90.

Arnold J, de Boer EC, O'Donnell MA, Bohle A, Brandau S: Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 2004;27:116-23.

O'Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK: The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder. J Urol 2004;171:1336-42.

O'Donnell MA, Luo Y, Hunter SE, Chen X, Hayes LL, Clinton SK: Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. J Urol 2004;171:1330-5.

Nadler R, Luo Y, Zhao W, Ritchey JK, Austin C, Cohen MB, O’Donnell MA, Ratliff TL: Augmentation of Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced antitumor activity by enhancing delayed type hypersensitivity (DTH). Clin Exp Immunol 2003;131:206-16.

Luo Y, Chen X, O’Donnell MA: Role of Th1 and Th2 cytokines in bacillus Calmette-Guerin (BCG)-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003;21:17-26.

Lam JS, Benson MC, O’Donnell MA, Sawczuk A, Gavazzi A, Wechsler M, Sawczuk IS: Bacillus Calmette-Guerin plus interferon alfa 2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 2003;21: 354-60.

Weiss GR, O’Donnell M, Loughlin K, Dillman K, Laliberte R, Sherman M: A phase I study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 2003;26:343-8.

Young S, O’Donnell M, Lockhart E, Buddle B, Slobbe L, Luo Y, DeLisle G, Buchan G: Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2 and IL-18 secreting recombinant BCG. Immunol Cell Biol 2002;80:209-15.

Young SL, O’Donnell MA, Buchan GS: IL-2-secreting recombinant bacillus Calmette Guerin can overcome a type 2 immune response and corticosteroid-induced immunosuppression to elicit a type 1 immune response. Int Immunol 2002;7:793-800.

He J, Shen D, O’Donnell MA, Chan HR: Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2. Int J Oncol 2002;20:1305-11.

Luo Y, Chen X, Han R, O’Donnell MA: Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:264-70.

O’Donnell, MA, Krohn J, DeWolf WC: Salvage intravesical therapy with interferon-alfa 2B plus low dose BCG is effective in patients with superficial bladder cancer previously failing BCG alone. J Urol 2001;166:1300-5.

Maranchie JK, Bouyounes BT, Zhang PL, O’Donnell MA, Summerhayes IC, DeWolf WC: Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 2000;163:748-751.

Pavlovich CP, Kraling BM, Stewart RJ, Chen X, Bochner BH, Luster AD, Poppas DP, O’Donnell MA: BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol 2000;163:2014-2021.

Luo Y, Chen X, Szilvasi A, O’Donnell MA: Co-expression of interleukin-2 and green flourescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity. Mol Immunol 2000;37:527-36.

Luo Y, Chen X, Downs T, DeWolf WC, O’Donnell MA: Interferon-alfa 2B enhances BCG-induced T helper type one responses in patients undergoing intravesical immunotherapy. J Immunol 1999;162:2399-2405.

Slobbe L, Lockhart E, O’Donnell MA, Mackintosh C, Buchan G: An in vivo comparison of BCG and cytokine secreting BCG vaccines. Immunology 1999;96:517-523.

Luo Y, Chen X, Han R, Chorev M, DeWolf WC, O’Donnell MA: Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma (TCC). J Urol 1999;162;1519-1526.

O’Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK: Role of IL-12 in the induction and potentiation of IFN-gamma in response to Bacillus Calmette-Guérin (BCG). J Immunol 1999;163:4246-4252.

Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O’Donnell MA, Clinton S, Alexandroff AB, Selby PJ, James K, Kuznetsov VA. Prognosis of bacillus Calmette-Guerin therapy of superfical bladder cancer by immunological urinary measurements: Statistically weighted syndromes analysis. J Urol 1998;159:1054-63

Poppas DP, Folkman J, Pavlovich CP, Voest E, Chen X, Luster AD, O’Donnell MA: Intravesical BCG induces the anti-angiogenic chemokine IP-10. Urology 1998;52:268-76.

Chen L, Chen D, Block E, O’Donnell MA, Kufe DW, Clinton SK: Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 1997;159:351-9.

Downs TM, Szilvasi A, O’Donnell MA: Pharmacological biocompatibility between intravesical prepartions of BCG and inteferon-alfa 2B. J Urol 1997;158:2311-15.

Fujimoto T, O’Donnell MA, Szilvasi A, Yang H, Duda RB: Bacillus Calmette-Guerin plus IL-2 and/or GMCSF enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 1996;42:280-4.

Luo Y, Szilvasi A, Chen X, DeWolf WC, O’Donnell MA: A novel method for monitoring Mycobacterium bovis BCG trafficking using recombinant BCG expressing green fluorescent protein. Clin Diag Lab Immunol 1996;3:761-8.

O’Donnell MA, Aldovini A, Duda RB, Yang H, Young R, DeWolf, WC: Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994;62:2508-14.

Recent Abstracts

Yamada H, Luo Y, O’Donnell MA. Differential chemokine expression by bladder cancer as a potential regulator of local immunotherapeutic responses. J Urol 2002;167(4 suppl):115, no. 458.

Yamada H, Luo Y, O’Donnell MA. IFN-gamma up-regulates toll-like receptor 4 functions and cooperates with LPS to produce MDC and IP-10 in human bladder cancer cell line RT4. J Urol 2002;167(4 suppl):7, no. 29.

Luo Y, Chen X, O’Donnell MA. Recombinant BCG expressing IL-18 enhances immune responses to mycobacterium and foreign immunogen. J Urol suppl 2002;167(4 suppl):115, no. 460.

O’Donnell MA, Hartman K, National Phase II BCG/IFN-alpha Investigator Group. An evaluation of BCG plus interferon-alpha-2B toxicity in a national multicenter phase II trial. J Urol 2002;167(4 suppl):188, no. 760.

Lam JS, Benson MC, O’Donnell MA, Sawczuk A, Gavazzi A, Wechsler M, Sawczuk IS. Bacillus Calmette-Guerin plus interferon alfa 2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. J Urol 2002;167(4 suppl):190, no. 765.

O’Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter phase II trial of combination BCG plus interferon-alfa-2B for superficial bladder cancer. J Urol 2003;169(4 suppl):256, no. 993.

O’Donnell MA, Evanoff D, Luo Y. Studies on gemcitabine as an intravesical agent for superficial bladder cancer. J Urol 2003;169(4 suppl):131, no. 508.

Luo Y, Chen X, O’Donnell MA. Use of PSA to measure tumor growth in an orthotopic bladder cancer model. J Urol 2003;169(4 suppl):131, no. 505.

Luo Y, Yamada H, Chen X, O’Donnell MA. Recombinant BCG expressing IL-18 (IL-18 rBCG) enhances macrophage cytotoxicity against mouse bladder cancer cell line MBT-2 in vitro. J Urol2003;169 (4 suppl):128, no. 496.

Selected Book Chapters

O’Donnell MA. Bladder cancer, TCC, superficial (CIS, Ta, T1). In Gomella and Dambro, eds., 5 Minute Urology Consult. Baltimore: Williams & Wilkins, 2000.

O'Donnell MA. Intravesical therapy. In Kursh and Ulchaker, eds., Office Urology. Totowa, NJ: Humana Press, Inc., 2000.

O’Donnell MA. Use of Intravesical BCG in treatment of superficial bladder cancer. In: Droller, ed., Bladder Cancer: Current Diagnosis and Treatment. Totowa NJ: Humana Press Inc., 2001.

O’Donnell MA. Superficial bladder cancer. In Furie, Cassileth, Atkins, Mayer, eds., Clinical Hematology and Oncology: Presentation, Diagnosis, and Treatment. Philadelphia: Churchill Livingston, 2003.

O’Donnell MA, Burns J. Intravesical BCG in treatment and prophylaxis of urothelial bladder cancer. In Droller, ed., Urothelial Cancer: American Cancer Society Atlas of Clinical Oncology. Hamilton Ontario: BC Decker, Inc., 2003.